Patents by Inventor Alessandra D'ANGELO
Alessandra D'ANGELO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220406435Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: ApplicationFiled: August 18, 2022Publication date: December 22, 2022Applicant: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Publication number: 20220260471Abstract: An apparatus, method and computer program is described, comprising: rotating a rotatable frame within a liquid provision chamber; providing liquid to a sample on the rotatable frame; obtaining a plurality of images of the sample from a plurality of angles over a first time period; and obtaining a three-dimensional model of the sample based on said plurality of images, wherein the three-dimensional model of the sample comprises quantitative information regarding at least one effect on the sample over the first time period in response to the provision of the liquid.Type: ApplicationFiled: June 29, 2020Publication date: August 18, 2022Applicant: University of GreenwichInventors: Milan ANTONIJEVIC, Mike READING, Alessandra D'ANGELO
-
Patent number: 11028415Abstract: A process for the production of lipids from biomass derived from guayule plants comprising: obtaining a hydrolysate comprising 5 carbon atom (C5) sugars from biomass derived from guayule plants, said 5 carbon atom (C5) sugars being present in said hydrolysate in a quantity greater than or equal to 80% by weight, preferably ranging from 85% by weight to 99% by weight, with respect to the total weight of said hydrolysate; feeding said hydrolysate to a fermentation device in the presence of at least one oleaginous yeast to obtain a fermentation broth; at the end of fermentation, subjecting said fermentation broth to separation obtaining an aqueous suspension of oleaginous cellular biomass comprising lipids and an aqueous phase. The lipids thus obtained can be advantageously used in the production of biofuel such as, for example, biodiesel or green diesel that can be used as such, or in mixtures with other fuels, for automotive transport.Type: GrantFiled: June 26, 2018Date of Patent: June 8, 2021Assignees: Versalis S.P.A., Eni S.P.A.Inventors: Daniela Cucchetti, Ezio Battistel, Chiara Gambaro, Alessandra D'Arminio Monforte
-
Publication number: 20200248214Abstract: A process for the production of lipids from biomass derived from guayule plants comprising: obtaining a hydrolysate comprising 5 carbon atom (C5) sugars from biomass derived from guayule plants, said 5 carbon atom (C5) sugars being present in said hydrolysate in a quantity greater than or equal to 80% by weight, preferably ranging from 85% by weight to 99% by weight, with respect to the total weight of said hydrolysate; feeding said hydrolysate to a fermentation device in the presence of at least one oleaginous yeast to obtain a fermentation broth; at the end of fermentation, subjecting said fermentation broth to separation obtaining an aqueous suspension of oleaginous cellular biomass comprising lipids and an aqueous phase. The lipids thus obtained can be advantageously used in the production of biofuel such as, for example, biodiesel or green diesel that can be used as such, or in mixtures with other fuels, for automotive transport.Type: ApplicationFiled: June 26, 2018Publication date: August 6, 2020Inventors: Daniela CUCCHETTI, Ezio BATTISTEL, Chiara GAMBARO, Alessandra D'ARMINIO MONFORTE
-
Publication number: 20200087704Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: ApplicationFiled: November 26, 2019Publication date: March 19, 2020Applicant: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Patent number: 10533208Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: GrantFiled: November 9, 2017Date of Patent: January 14, 2020Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Ida Annunziata, Alessandra D'Azzo
-
Publication number: 20180185794Abstract: The present invention relates to a reaction device with air-lift type internal circulation which includes:—a vertical cylindrical volume;—a vertical element positioned within said volume in such a way as to form an interspace with the walls of said volume, having a cross-section which is circular and orthogonal to the vertical axis of the element and with a variable internal diameter along said axis, said element being denoted “draft tube”;—at least one gas distributor positioned on the bottom of said device; said device being characterised in that:—the ratio between the diameter of the internal vertical element and the internal diameter of the cylindrical volume ranges from 0.05 to 0.5, and—the ratio between the height of the vertical element and the height of the cylindrical volume is less than 0.5.Type: ApplicationFiled: September 15, 2016Publication date: July 5, 2018Inventors: Fabio OLDANI, Alessandra D'ARMINIO MONFORTE
-
Publication number: 20180057854Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: ApplicationFiled: November 9, 2017Publication date: March 1, 2018Applicant: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Patent number: 9840727Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: GrantFiled: June 20, 2016Date of Patent: December 12, 2017Assignee: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Patent number: 9629969Abstract: The invention concerns a product consisting of distilled water or of an aqueous solution hypotonic or substantially isotonic with respect to blood plasma or, less preferably, hypertonic with respect to blood plasma, to be administered on the nasal mucosa according to a specific operation mode in order to cause an inflammation of an irritative kind, for use in a treatment of stimulation of the endogenous production of inflammatory mediators, in the therapy and prevention of neurological disorders, in particular of degenerative disorders of the central and peripheral nervous system. The inflammatory mediators the endogenous production of which is stimulated comprise NGF, neurotrophin-3, neurotrophin-4, serotonin, substance P, heparin, ECF-A.Type: GrantFiled: July 20, 2012Date of Patent: April 25, 2017Inventors: Fabrizio Salvinelli, Beatrice Salvinelli, Emanuele Salvinelli, Alessandra D'Eramo
-
Publication number: 20160304933Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: ApplicationFiled: June 20, 2016Publication date: October 20, 2016Applicant: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Patent number: 9399791Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: GrantFiled: August 28, 2012Date of Patent: July 26, 2016Assignee: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo
-
Publication number: 20140377245Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: ApplicationFiled: August 28, 2012Publication date: December 25, 2014Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Publication number: 20140290647Abstract: The invention concerns a product consisting of distilled water or of an aqueous solution hypotonic or substantially isotonic with respect to blood plasma or, less preferably, hypertonic with respect to blood plasma, to be administered on the nasal mucosa according to a specific operation mode in order to cause an inflammation of an irritative kind, for use in a treatment of stimulation of the endogenous production of inflammatory mediators, in the therapy and prevention of neurological disorders, in particular of degenerative disorders of the central and peripheral nervous system. The inflammatory mediators the endogenous production of which is stimulated comprise NGF, neurotrophin-3, neurotrophin-4, serotonin, substance P, heparin, ECF-A.Type: ApplicationFiled: July 20, 2012Publication date: October 2, 2014Inventors: Fabrizio Salvinelli, Beatrice Salvinelli, Emanuele Salvinelli, Alessandra d'Eramo
-
Publication number: 20140193392Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: ApplicationFiled: August 28, 2012Publication date: July 10, 2014Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Patent number: 7425615Abstract: The present invention relates to a muscle-specific protein, Ozz, and nucleic acids encoding the protein, that regulates development and function of muscle cells. The invention further relates to muscle-specific regulated expression of the protein, and of heterologous genes under control of the same regulatory sequences. In a specific example, a murine Ozz protein of 285 amino acids is preferentially expressed by a 1.0 kb mRNA in heart and skeletal muscle. This protein shares significant homology with neuralized proteins, and associates with a number of muscle proteins, including ?-catenin.Type: GrantFiled: May 23, 2006Date of Patent: September 16, 2008Assignee: St. Jude Children's Research HospitalInventors: Alessandra D'azzo, Antonella Bongiovanni, Tommaso Nastasi
-
Patent number: 7241442Abstract: The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.Type: GrantFiled: December 11, 2003Date of Patent: July 10, 2007Assignee: St. Jude Children's Research HospitalInventors: Alessandra D'Azzo, Erik Jacobus Bonten
-
Patent number: 7232670Abstract: The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.Type: GrantFiled: September 28, 2001Date of Patent: June 19, 2007Assignee: St. Jude Children's Research HospitalInventors: Alessandra D'Azzo, Erik Jacobus Bonten
-
Publication number: 20060236410Abstract: The present invention relates to a muscle-specific protein, Ozz, and nucleic acids encoding the protein, that regulates development and function of muscle cells. The invention further relates to muscle-specific regulated expression of the protein, and of heterologous genes under control of the same regulatory sequences. In a specific example, a murine Ozz protein of 285 amino acids is preferentially expressed by a 1.0 kb mRNA in heart and skeletal muscle. This protein shares significant homology with neuralized proteins, and associates with a number of muscle proteins, including ?-catenin.Type: ApplicationFiled: May 23, 2006Publication date: October 19, 2006Applicant: St. Jude Children's Research HospitalInventors: Alessandra D'Azzo, Antonella Bongiovanni, Tommaso Nastasi
-
Patent number: 7074908Abstract: The present invention relates to a muscle-specific protein, Ozz, and nucleic acids encoding the protein, that regulates development and function of muscle cells. The invention further relates to muscle-specific regulated expression of the protein, and of heterologous genes under control of the same regulatory sequences. In a specific example, a murine Ozz protein of 285 amino acids is preferentially expressed by a 1.0 kb mRNA in heart and skeletal muscle. This protein shares significant homology with neuralized proteins, and associates with a number of muscle proteins, including ?-catenin.Type: GrantFiled: October 29, 2001Date of Patent: July 11, 2006Assignee: St. Jude Children's Research HospitalInventors: Alessandra D'Azzo, Antonella Bongiovanni, Tommaso Nastasi